QQQ   293.34 (+1.95%)
AAPL   143.96 (+1.48%)
MSFT   248.00 (+3.07%)
META   147.30 (+4.10%)
GOOGL   97.52 (+2.42%)
AMZN   99.22 (+2.10%)
TSLA   160.27 (+10.97%)
NVDA   198.02 (+2.48%)
NIO   12.17 (+4.64%)
BABA   120.57 (+0.27%)
AMD   75.16 (+0.33%)
T   20.00 (-2.06%)
MU   62.80 (+2.05%)
F   12.92 (+1.02%)
CGC   2.76 (+0.00%)
GE   81.14 (+0.43%)
DIS   109.70 (+1.46%)
AMC   5.28 (-0.94%)
PFE   44.25 (-1.82%)
PYPL   80.81 (+2.16%)
NFLX   364.87 (-0.84%)
QQQ   293.34 (+1.95%)
AAPL   143.96 (+1.48%)
MSFT   248.00 (+3.07%)
META   147.30 (+4.10%)
GOOGL   97.52 (+2.42%)
AMZN   99.22 (+2.10%)
TSLA   160.27 (+10.97%)
NVDA   198.02 (+2.48%)
NIO   12.17 (+4.64%)
BABA   120.57 (+0.27%)
AMD   75.16 (+0.33%)
T   20.00 (-2.06%)
MU   62.80 (+2.05%)
F   12.92 (+1.02%)
CGC   2.76 (+0.00%)
GE   81.14 (+0.43%)
DIS   109.70 (+1.46%)
AMC   5.28 (-0.94%)
PFE   44.25 (-1.82%)
PYPL   80.81 (+2.16%)
NFLX   364.87 (-0.84%)
QQQ   293.34 (+1.95%)
AAPL   143.96 (+1.48%)
MSFT   248.00 (+3.07%)
META   147.30 (+4.10%)
GOOGL   97.52 (+2.42%)
AMZN   99.22 (+2.10%)
TSLA   160.27 (+10.97%)
NVDA   198.02 (+2.48%)
NIO   12.17 (+4.64%)
BABA   120.57 (+0.27%)
AMD   75.16 (+0.33%)
T   20.00 (-2.06%)
MU   62.80 (+2.05%)
F   12.92 (+1.02%)
CGC   2.76 (+0.00%)
GE   81.14 (+0.43%)
DIS   109.70 (+1.46%)
AMC   5.28 (-0.94%)
PFE   44.25 (-1.82%)
PYPL   80.81 (+2.16%)
NFLX   364.87 (-0.84%)
QQQ   293.34 (+1.95%)
AAPL   143.96 (+1.48%)
MSFT   248.00 (+3.07%)
META   147.30 (+4.10%)
GOOGL   97.52 (+2.42%)
AMZN   99.22 (+2.10%)
TSLA   160.27 (+10.97%)
NVDA   198.02 (+2.48%)
NIO   12.17 (+4.64%)
BABA   120.57 (+0.27%)
AMD   75.16 (+0.33%)
T   20.00 (-2.06%)
MU   62.80 (+2.05%)
F   12.92 (+1.02%)
CGC   2.76 (+0.00%)
GE   81.14 (+0.43%)
DIS   109.70 (+1.46%)
AMC   5.28 (-0.94%)
PFE   44.25 (-1.82%)
PYPL   80.81 (+2.16%)
NFLX   364.87 (-0.84%)
NASDAQ:INSM

Insmed - INSM Stock Forecast, Price & News

$21.46
-0.13 (-0.60%)
(As of 01/26/2023 04:13 PM ET)
Add
Compare
Today's Range
$20.99
$21.95
50-Day Range
$17.79
$21.59
52-Week Range
$16.41
$28.94
Volume
643,652 shs
Average Volume
1.52 million shs
Market Capitalization
$2.91 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.36

Insmed MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
103.8% Upside
$43.36 Price Target
Short Interest
Bearish
7.95% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.29
Upright™ Environmental Score
News Sentiment
0.23mentions of Insmed in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$875,661 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.65) to ($3.71) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

386th out of 1,048 stocks

Pharmaceutical Preparations Industry

188th out of 513 stocks


INSM stock logo

About Insmed (NASDAQ:INSM) Stock

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Receive INSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter.

INSM Stock News Headlines

Insmed (NASDAQ:INSM) Given New $35.00 Price Target at Barclays
Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
Insmed (NASDAQ:INSM) Price Target Lowered to $35.00 at Barclays
Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
Analyst Ratings for Insmed
Insmed To Present at the Nasdaq 47th Investor Conference
Insmed Director Trades Company's Stock
Insmed To Present at Three November Conferences
Why Insmed's Shares Fell 14.7% on Wednesday
Form 8-K INSMED Inc For: Oct 19 - StreetInsider.com
See More Headlines
Receive INSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter.

INSM Company Calendar

Last Earnings
10/28/2021
Today
1/26/2023
Next Earnings (Estimated)
2/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INSM
Employees
373
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$43.36
High Stock Price Forecast
$53.00
Low Stock Price Forecast
$28.00
Forecasted Upside/Downside
+102.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-434,650,000.00
Net Margins
-179.37%
Pretax Margin
-178.86%

Debt

Sales & Book Value

Annual Sales
$188.46 million
Book Value
$3.47 per share

Miscellaneous

Free Float
129,204,000
Market Cap
$2.91 billion
Optionable
Optionable
Beta
1.49

Social Links


Key Executives

  • Mr. William H. Lewis J.D.Mr. William H. Lewis J.D. (Age 50)
    Pres, CEO & Chairman
  • Mr. Paolo Tombesi (Age 55)
    Chief Financial Officer
  • Ms. Christine A. Pellizzari J.D. (Age 51)
    Chief Legal Officer & Corp. Sec.
  • Mr. Roger  AdsettMr. Roger Adsett (Age 50)
    Chief Commercial Officer
  • Dr. Paul D. Streck (Age 55)
    Advisor













INSM Stock - Frequently Asked Questions

Should I buy or sell Insmed stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INSM shares.
View INSM analyst ratings
or view top-rated stocks.

What is Insmed's stock price forecast for 2023?

9 brokers have issued twelve-month price objectives for Insmed's shares. Their INSM share price forecasts range from $28.00 to $53.00. On average, they expect the company's stock price to reach $43.36 in the next twelve months. This suggests a possible upside of 106.5% from the stock's current price.
View analysts price targets for INSM
or view top-rated stocks among Wall Street analysts.

How have INSM shares performed in 2023?

Insmed's stock was trading at $19.98 at the start of the year. Since then, INSM stock has increased by 5.1% and is now trading at $21.00.
View the best growth stocks for 2023 here
.

When is Insmed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our INSM earnings forecast
.

How were Insmed's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) released its quarterly earnings results on Thursday, October, 28th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by $0.13. The biopharmaceutical company had revenue of $46.80 million for the quarter, compared to the consensus estimate of $49.23 million. Insmed had a negative trailing twelve-month return on equity of 319.03% and a negative net margin of 179.37%. The company's revenue was up 6.8% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.63) EPS.

What guidance has Insmed issued on next quarter's earnings?

Insmed issued an update on its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $245.00M-, compared to the consensus revenue estimate of $257.22 million.

What is Will Lewis' approval rating as Insmed's CEO?

14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees.

What other stocks do shareholders of Insmed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN).

What is Insmed's stock symbol?

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Who are Insmed's major shareholders?

Insmed's stock is owned by a number of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.77%), Peregrine Capital Management LLC (0.26%), Scout Investments Inc. (0.24%), Hennion & Walsh Asset Management Inc. (0.10%), Oak Ridge Investments LLC (0.06%) and Allspring Global Investments Holdings LLC (0.03%). Insiders that own company stock include Alfred Altomari, Christine A Pellizzari, David R Brennan, John Drayton Wise, John Soriano, Martina MD Flammer, Melvin Md Sharoky, Michael Alexander Smith, Orlov S Nicole Schaeffer, Roger Adsett, Sara Bonstein and William Lewis.
View institutional ownership trends
.

How do I buy shares of Insmed?

Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insmed's stock price today?

One share of INSM stock can currently be purchased for approximately $21.00.

How much money does Insmed make?

Insmed (NASDAQ:INSM) has a market capitalization of $2.85 billion and generates $188.46 million in revenue each year. The biopharmaceutical company earns $-434,650,000.00 in net income (profit) each year or ($3.64) on an earnings per share basis.

How many employees does Insmed have?

The company employs 373 workers across the globe.

How can I contact Insmed?

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The official website for the company is www.insmed.com. The biopharmaceutical company can be reached via phone at 908-977-9900, via email at investor.relations@insmed.com, or via fax at 732-438-0381.

This page (NASDAQ:INSM) was last updated on 1/26/2023 by MarketBeat.com Staff